NEW HAVEN, Conn., June 21, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...
Platform screens up to 10 billion compounds in hours, delivering wet-lab-ready candidates in weeks without requiring 3D ...
Cancer therapies sometimes involve drugs that mediate the breakdown of specific intracellular proteins that participate in cancer formation and proliferation. Proteolysis-targeting chimeras or PROTACs ...
The PROTAC market is experiencing rapid growth, driven by rising interest in targeted protein degradation as a next-generation therapeutic approach. Expanding oncology pipelines with drugs in clinical ...
I tested the Streamlights PROTAC HL® 4 HIGH LUMEN TACTICAL LIGHT, a dual power hand torch that throws can throw a beam out to 346 meters. The PROTAC HL® 4 is 8.63 inches long and weighs 1.1 lbs. It is ...
This article and associated images are based on a poster originally authored by Kieran Casey, Yuzhou Xu, Jichuan Zhang, Shuyue Wang, Yanfei Hu, Ye Tian, Min Lyu, Ziyu Chen, Ya Xu, Qikuan Chen and ...
EAGLEVILLE, PA - Streamlight Inc., a leading provider of high-performance lighting, introduced the ProTac 2.0 HP tactical flashlight, delivering 85,000 candela for powerful downrange illumination, ...
Proteolysis Targeting Chimeras (PROTACs) are a novel approach for degrading target proteins. Recently, a new split-and-mix PROTAC (SM-PROTAC) system based on liposome self-assembly, known as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results